

Supplementary File

Recent Advances in Small Peptides of Marine Origin in Cancer Therapy

Qi-Ting Zhang¹, Ze-Dong Liu², Ze Wang², Tao Wang¹, Nan Wang³, Ning Wang^{1,*}, Bin Zhang^{2,*} and Yu-Fen Zhao¹

¹ Institute of Drug Discovery Technology, Ningbo University, Ningbo, Zhejiang, 315211, PR China

² Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Research Center, Department of Marine Pharmacy, College of Food and Pharmaceutical Sciences, Ningbo University, Ningbo, Zhejiang, 315800, PR China

³ Shenzhen Kivita Innovative Drug Discovery Institute, Shenzhen, Guangdong, 518057, PR China

* Correspondence: wangning2@nbu.edu.cn (N.W.); zhangbin1@nbu.edu.cn (B.Z.)

Table S1. Clinical information on Marine small peptide drugs

Compound	Condition or disease	ClinicalTrials.gov Identifier:	Clinical Trial	Status	Study Completion Date
E7974	Advanced Solid Tumors	NCT00165802	Phase I	Completed.	January 2009
	Solid Malignancies	NCT00130169	Phase I	Completed.	August 2009
	Solid Malignancies	NCT00121732	Phase I	Completed.	October 2009
HTI-286 (Taltobulin)	Advanced solid tumours [1]	- ^a	phase I	Completed.	2002
Dolastatin 10 (NSC#376128)	Metastatic Prostate Cancer	NCT00003626	Phase II	Completed.	May 2000
	Recurrent or Metastatic Soft Tissue Sarcoma	NCT00003778	Phase II	Completed.	July 2000
	Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia	NCT00003693	Phase I	Completed.	October 30, 2001
	Metastatic Pancreatic Cancer	NCT00003677	Phase II	Completed.	January 2002
	Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia	NCT00005579	Phase II	Completed.	February 2003
	Metastatic or Recurrent Liver, Bile Duct or Gallbladder Cancer	NCT00003557	Phase II	Completed.	August 2003
	Advanced Kidney Cancer	NCT00003914	Phase II	Completed.	May 2009
TZT-1027	Progressive Locally Advanced or Metastatic Non-Small Cell Lung Cancer	NCT00061854	Phase II	Completed.	May 2005
	Advanced or Metastatic Soft Tissue Sarcoma	NCT00064220	Phase II	Completed.	December 2005
ILX-651 (Tasidotin)	Locally Advanced or Metastatic Non-Small Cell, Lung Carcinoma Small Cell, Lung Carcinoma	NCT00078455	Phase II	Completed.	August 2005

	Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel	NCT00082134	Phase II	Completed.	December 2005
	Inoperable Locally Advanced or Metastatic Melanoma	NCT00068211	Phase II	Completed.	January 2006
Cematodin (LU103793)	Refractory Metastatic Solid Tumors [2]	-a	Phase I	Completed.	1996
Glembatumumab vedotin (CDX-011)	Unresectable Stage III or Stage IV Melanoma	NCT00412828	Phase I Phase II	Completed.	May 2011
	Locally Advanced or Metastatic Breast Cancer	NCT00704158	Phase I Phase II	Completed.	June 2011
	Advanced GPNMB-expressing Breast Cancer	NCT01156753	Phase II	Completed.	November 2012
	Recurrent or Refractory Osteosarcoma	NCT02487979	Phase II	Completed.	June 30, 2017
	Metastatic or Locally Recurrent Uveal Melanoma	NCT02363283	Phase II	Completed.	July 2, 2018
	Metastatic, gpNMB Over-Expressing Triple Negative Breast Cancer	NCT01997333	Phase II	Completed.	August 7, 2018
	gpNMB-Expressing, Advanced or Metastatic SCC of the Lung	NCT02713828	Phase I Phase II	Terminated. Has Results	September 26, 2018
	Immunotherapies in Patients with Advanced Melanoma	NCT02302339	Phase II	Terminated. Has Results	October 3, 2018
Brentuximab vedotin (SGN-35, Monomethyl Auristatin E, Adcetris.)	A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study	NCT00947856	Phase II	Completed.	March 2013
	Relapsed or Refractory Hodgkin Lymphoma	NCT00337194	Phase II	Completed.	October 2014
	CD30-positive Nonlymphomatous Malignancies	NCT01461538	Phase II	Completed.	December 2014
	Hodgkin Lymphoma	NCT00848926	Phase II	Completed.	May 2015
	Relapsed or Refractory Non-Hodgkin	NCT01421667	Phase II	Completed.	June 2015

	Lymphoma				
	Mycosis Fungoides With Variable CD30 Expression Level	NCT01396070	Phase II	Completed.	May 2016
	Systemic Anaplastic Large Cell Lymphoma	NCT00866047	Phase II	Completed.	June 2016
	Relapsed or Refractory PMLBCL (FIL_SGN01)	NCT02423291	Phase II	Completed.	July 2016
	Hodgkin Lymphoma	NCT01393717	Phase II	Completed.	February 1, 2017
	Advanced Systemic Mastocytosis or Mast Cell Leukemia	NCT01807598	Phase II	Completed.	September 2017
	Limited-stage Hodgkin Lymphoma	NCT01534078	Phase II	Completed.	January 2018
	Hodgkin Lymphoma	NCT01874054	Phase I Phase II	Completed.	February 20, 2018
	Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma	NCT01492088	Phase I Phase II	Completed.	April 12, 2018
	CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) (ALCANZA)	NCT01578499	Phase III	Completed.	July 6, 2018
	Non-bulky Limited Stage Hodgkin Lymphoma	NCT02505269	Phase II	Completed.	June 2019
	Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)	NCT02939014	Phase II	Completed	February 3, 2020
	High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)	NCT01100502	Phase III	Completed.	April 27, 2020
	CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients	NCT01994850	Phase I Phase II	Completed.	January 5, 2021

	Relapsed or Refractory Hodgkin Lymphoma	NCT01990534	Phase IV	Completed.	June 10, 2021
Didemnin B (NSC 325319)	Advanced Epithelial Ovarian Cancer [3].	- ^a	Phase II	Completed.	1992
	Metastatic Breast Cancer [4].	- ^a	Phase I	Completed.	1992
	Myeloma. A Cancer and Leukemia [5].	- ^a	phase II	Completed.	1994
	Advanced Malignant Melanoma [6]	- ^a	phase II	Completed	1998
	Central Nervous System Tumors [7]	- ^a	Phase II	Completed.	1999
	Recurrent or Refractory Anaplastic Astrocytoma or Glioblastoma Multiforme [8]	- ^a	Phase II	Completed.	1999
	Previously Treated Non-Hodgkin's lymphoma [9]	- ^a	Phase II	Completed	2000
Aplidine (Dehydroidemnin B)	Advanced Prostate Cancer	NCT00780975	Phase II	Terminated. Has Results	March 2008
	Relapsing or Refractory Multiple Myeloma	NCT00229203	Phase II	Completed.	August 2008
	Relapsed/Refractory Leukemia	NCT00780143	Phase I Phase II	Completed.	June 2009
	Relapsed/Refractory Aggressive Non Hodgkin Lymphoma	NCT00884286	Phase II	Terminated. Has Results	June 2010
	Primary Myelofibrosis	NCT01149681	Phase II	Terminated. Has Results	February 2011
	Advanced Solid Tumors or Lymphomas	NCT00788099	Phase I	Completed.	June 2011
	Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS)	NCT01876043	Phase II	Terminated. Has Results	April 2015
	Relapsed/Refractory Myeloma (ADMYRE)	NCT01102426	Phase III	Completed.	November 2017
	Multiple Myeloma	NCT02100657	Phase I	Completed.	June 2018
	Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide	NCT03117361	Phase II	Completed.	July 2018

	Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma	NCT03070964	Phase II	Terminated. Has Results	July 2018
	COVID-19 (APLICOV-PC)	NCT04382066	Phase I	Completed.	December 2020
Plinabulin	Advanced Solid Tumors or Lymphoma	NCT00322608	Phase I	Completed.	December 2009
	Advanced Non-Small Cell Lung Cancer	NCT00630110	Phase I Phase II	Completed.	June 2011
	Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2	NCT04345900	Phase II	Completed.	April 2018
	Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer	NCT02846792	Phase I Phase II	Terminated. Has Results	August 2018
	TAC Induced Neutropenia	NCT04227990	Phase II	Completed.	January 2019
	Advanced NSCLC (DUBLIN-3)	NCT02504489	Phase III	Recruiting.	November 2020
	Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 (Protective-1)	NCT03102606	Phase III	Active, not recruiting.	December 2020
	Recurrent Small Cell Lung Cancer	NCT03575793	Phase I Phase II	Recruiting.	September 2022
	Metastatic Non-Small Cell Lung Cancer (NSCLC)	NCT02812667	Phase I	Recruiting.	December 2022
	Prevention of TAC Induced Neutropenia	NCT03294577	Phase III	Active, not recruiting.	September 2025
Halimide	Advanced, Metastatic Non-small Cell Lung Cancer [10]	- ^a	Phase II	Completed.	2015
LY355703	Inhibits the Growth of Various Tumour Cells [11]	- ^a	Phase II	Completed.	1998
	Phase I and pharmacological Studies of the Cryptophycin Analogue LY355703 Administered [12]	- ^a	Phase I	Completed.	2002

Notes: -^a Data not mentioned.

References

1. Ratain, M.J.; Undevia, S.; Janisch, L.; Roman, S.; Mayer, P.; Buckwalter, M.; Foss, D.; Hamilton, B.L.; Fischer, J.; Bukowski, R.M. Phase I and pharmacological study of HTI-286, a novel antimicrotubule agent: correlation of neutropenia with time above threshold plasma concentration. *Proc Am Soc Clin Oncol*, **2003**, *129*, abstract 516.
2. Poruchynsky, M.S.; Kim, J.H.; Nogales, E.; Annable, T.; Loganzo, F.; Greenberger, L.M.; Sackett, D.L.; Fojo, T. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability. *Biochemistry* **2004**, *43*, 13944-13954, doi:10.1021/bi049300+.
3. Cain, J.M.; Liu, P.Y.; Alberts, D.E.; Gallion, H.H.; Laufman, L.; O'Sullivan, J.; Weiss, G.; Bickers, J.N. Phase II trial of didemnin-B in advanced epithelial ovarian cancer. A Southwest Oncology Group study. *Invest New Drugs* **1992**, *10*, 23-24, doi:10.1007/bf01275473.
4. Benvenuto, J.A.; Newman, R.A.; Bignami, G.S.; Raybould, T.J.; Raber, M.N.; Esparza, L.; Walters, R.S. Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer. *Invest New Drugs* **1992**, *10*, 113-117, doi:10.1007/bf00873128.
5. Weiss, R.B.; Peterson, B.L.; Allen, S.L.; Browning, S.M.; Duggan, D.B.; Schiffer, C.A. A phase II trial of didemnin B in myeloma. A cancer and leukemia group B (CALGB) study. *Invest. New Drugs* **1994**, *12*, 41-43, doi:10.1007/bf00873234.
6. Hochster, H.; Oratz, R.; Ettinger, D.S.; Borden, E. A phase II study of Didemnin B (NSC 325319) in advanced malignant melanoma: an eastern cooperative oncology group study (PB687). *Invest New Drugs* **1998**, *16*, 259-263, doi:10.1023/a:1006110431250.
7. Taylor, S.A.; Giroux, D.J.; Jaeckle, K.A.; Panella, T.J.; Dakhil, S.R.; Schold, S.C. Phase II study of Didemnin B in central nervous system tumors: a southwest oncology group study. *Invest New Drugs* **1998**, *16*, 331-332, doi:10.1023/a:1006273214056.
8. Mittelman, A.; Chun, H.G.; Puccio, C.; Coombe, N.; Larsen, T.; Ahmed, T. Phase II clinical trial of didemnin B in patients with recurrent or refractory anaplastic astrocytoma or glioblastoma multiforme (NSC 325319). *Invest New Drugs* **1999**, *17*, 179-182, doi:10.1023/a:1006379402114.
9. Kucuk, O.; Young, M.L.; Habermann, T.M.; Wolf, B.C.; Jimeno, J.; Cassileth, P.A. Phase II trial of didemnin B in previously treated non-Hodgkin's lymphoma: an eastern cooperative oncology group (ECOG) study. *Am J Clin Oncol* **2000**, *23*, 273-277, doi:10.1097/00000421-200006000-00013.
10. Millward, M.; Mainwaring, P.; Mita, A.; Federico, K.; Lloyd, G.K.; Reddinger, N.; Nawrocki, S.; Mita, M.; Spear, M.A. Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel. *Invest. New Drugs* **2012**, *30*, 1065-1073, doi:10.1007/s10637-011-9642-4.
11. Mooberry, S.L.; Busquets, L.; Tien, G. Induction of apoptosis by cryptophycin 1, a new antimicrotubule agent. *Int. J. Cancer* **1997**, *73*, 440-448, doi:10.1002/(sici)1097-0215(19971104)73:3<440::aid-ijc20>3.0.co;2-f.

12. Sessa, C.; Weigang-Köhler, K.; Pagani, O.; Greim, G.; Mora, O.; De Pas, T.; Burgess, M.; Weimer, I.; Johnson, R. Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule. *Eur. J. Cancer* **2002**, *38*, 2388-2396, doi:10.1016/s0959-8049(02)00489-6.